Melphalan flufenamide

Generic Name
Melphalan flufenamide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H30Cl2FN3O3
CAS Number
380449-51-4
Unique Ingredient Identifier
F70C5K4786
Background

Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased potency makes melphalan flufenamide a treat...

Indication

Melphalan flufenamide is indicated in combination with dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received ≥4 therapies and are refractory to at least one proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody. The FDA has withdrawn the drug from the market for this indication following phase ...

Associated Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Associated Therapies
-
Clinical Trials
Related News

Melflufen for Elderly Patients With Relapsed Myeloma

Phase 2
Not yet recruiting
Conditions
Relapse Multiple Myeloma
Interventions
Drug: Melflufen
Drug: Dexamethasone
First Posted Date
2024-11-12
Last Posted Date
2024-11-13
Lead Sponsor
Fondazione EMN Italy Onlus
Target Recruit Count
30
Registration Number
NCT06682637
Locations
🇮🇹

A.O.U. delle Marche, Ancona, Italy

🇮🇹

Ospedale Nuovo di Legnano, Legnano, Italy

🇮🇹

Ospedale Niguarda, Milano, Italy

and more 7 locations

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

First Posted Date
2020-12-02
Last Posted Date
2023-06-08
Lead Sponsor
Oncopeptides AB
Target Recruit Count
54
Registration Number
NCT04649060
Locations
🇵🇱

Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Kraków, Poland

🇧🇬

Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia, Bulgaria

🇨🇿

University Hospital Hradec Kralove, 4th Internal Clinic of Hematology, Kralovice, Czechia

and more 23 locations

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

First Posted Date
2020-09-01
Last Posted Date
2021-03-18
Lead Sponsor
Oncopeptides AB
Registration Number
NCT04534322
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

Gabrail Cancer Center, Canton, Ohio, United States

🇺🇸

Texas Oncology, Dallas, Texas, United States

and more 8 locations

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

First Posted Date
2018-08-21
Last Posted Date
2023-03-10
Lead Sponsor
Oncopeptides AB
Target Recruit Count
35
Registration Number
NCT03639610
Locations
🇨🇿

University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc, Czechia

🇬🇷

University General Hospital of Patras, Patra, Greece

🇬🇷

General Hospital of Athens Alexandra, Therapeutic Clinic, Athens, Greece

and more 7 locations

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

First Posted Date
2017-05-12
Last Posted Date
2024-01-30
Lead Sponsor
Oncopeptides AB
Target Recruit Count
495
Registration Number
NCT03151811
Locations
🇨🇿

CZ-01, Ostrava, Czechia

🇺🇸

US-19, Plantation, Florida, United States

🇺🇸

US01, Fresno, California, United States

and more 102 locations

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

First Posted Date
2013-07-12
Last Posted Date
2020-10-23
Lead Sponsor
Oncopeptides AB
Target Recruit Count
75
Registration Number
NCT01897714
Locations
🇮🇹

Turin Hospital Myeloma Unit, Turin, Italy

🇩🇰

Vejle Hospital, Vejle, Denmark

🇸🇪

Sahlgrenska Hospital, Gothenburg, Sweden

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy